Zymeworks (ZYME) Institutional Ownership

92.89% of Zymeworks' stock is owned by institutional investors. Learn more on ZYME's institutional investor holdings.

Of the 156 institutional investors that purchased Zymeworks' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: EcoR1 Capital LLC ($7.94M), Rubric Capital Management LP ($3.10M), UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC ($2.51M), Perceptive Advisors LLC ($2.01M), Vestal Point Capital LP ($1.76M), Siren L.L.C. ($1.68M), and Assenagon Asset Management S.A. ($1.56M).

Institutional investors have bought a total of 21,597,349 shares in the last 24 months. This purchase volume represents approximately $303.43M in transactions.

Of the 77 institutional investors that sold Zymeworks' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($299.47M), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ($2.14M), Morgan Stanley ($1.39M), Tang Capital Management LLC ($1.07M), Vestal Point Capital LP ($900K), JPMorgan Chase & Co. ($815.61K), and Prosight Management LP ($779.51K).

Institutional investors have sold a total of 312,612,591 shares in the last 24 months. This volume of shares sold represents approximately $262.83M in transactions.